Baillie Gifford & Co
HRTX icon

Baillie Gifford & Co’s Heron Therapeutics HRTX Stock Holding History

Baillie Gifford & Co’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-308
Closed -$465 – 362
2023
Q1 		$465 Hold
308
– – ﹤0.01% 450
2022
Q4 		$770 Hold
308
– – ﹤0.01% 481
2022
Q3 		$1K Hold
308
– – ﹤0.01% 481
2022
Q2 		$1K Hold
308
– – ﹤0.01% 485
2022
Q1 		$2K Hold
308
– – ﹤0.01% 490
2021
Q4 		$3K Hold
308
– – ﹤0.01% 492
2021
Q3 		$3K Hold
308
– – ﹤0.01% 486
2021
Q2 		$5K Hold
308
– – ﹤0.01% 464
2021
Q1 		$5K Sell
308
-18
-6% -$321 ﹤0.01% 434
2020
Q4 		$7K Buy
+326
New +$5.67K ﹤0.01% 404

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Baillie Gifford & Co's HRTX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 308 shares — an estimated $465 sold.

Baillie Gifford & Co first reported a position in HRTX in Q4 2020 and held it in 10 quarters. The position peaked at $7K in Q4 2020. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 308 Heron Therapeutics shares in Q2 2023, an estimated $465.
  • Baillie Gifford & Co first reported a position in Heron Therapeutics in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Heron Therapeutics position peaked at $7K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.